Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations | Zendy

Tsunefusa Hayashida | Zendy; Atsuko Hachiya | Zendy; Hirotaka Ode | Zendy; Takeshi Nishijima | Zendy; K. Tsuchiya | Zendy; Wataru Sugiura | Zendy; Masafumi Takiguchi | Zendy; Shinichi Oka | Zendy; Hiroyuki Gatanaga | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations

Author(s) -

Tsunefusa Hayashida,

Atsuko Hachiya,

Hirotaka Ode,

Takeshi Nishijima,

K. Tsuchiya,

Wataru Sugiura,

Masafumi Takiguchi,

Shinichi Oka,

Hiroyuki Gatanaga

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw224

Subject(s) - rilpivirine , virology , reverse transcriptase , drug resistance , human immunodeficiency virus (hiv) , medicine , resistance mutation , mutation , viral load , biology , genetics , polymerase chain reaction , gene , antiretroviral therapy

Rilpivirine is listed as a recommended or alternative key drug in the current ART guidelines. E138K in HIV-1 reverse transcriptase (RT) is a primary mutation in resistance to rilpivirine, although in vitro experiments showed it confers only <3-fold resistance. An unidentified mechanism could amplify resistance to rilpivirine conferred by E138K.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research